Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.53 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.53 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 5/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232471 | 0.92 | TSHR (0.42) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL3291702 | 0.85 | CACNA2D1 (0.53) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL15969817 | 0.85 | CACNA2D1 (0.53) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL3291696 | 0.85 | CACNA2D1 (0.53) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL665555 | 0.82 | CACNA2D1 (0.59) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4888997 | 0.82 | CACNA2D1 (0.50) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1410027 | 0.82 | CACNA2D1 (0.74) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL665175 | 0.81 | CACNA2D1 (0.57) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL664788 | 0.81 | CACNA2D1 (0.57) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4194017 | 0.81 | CACNA2D1 (0.57) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311635-A1 | PROCESS FOR THE PREPARATION OF (S)(+)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | DIPHARMA FRANCIS S.R.L. (IT) | 2008-12-18 | — | — | US | disclosed |
| EP-1992609-A1 | A process for the preparation of a (S)(+)-3-(aminomethyl)-5-methylhexanoic acid | Dipharma Francis S.r.l. (IT) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311635-A1 | PROCESS FOR THE PREPARATION OF (S)(+)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | ADH5, ALDH7A1, ADH1C | CACNA2D1 360/4885CACNB3 575/4885CACNA1C 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.